Interleukin-10 and articular cartilage: Experimental therapeutical approaches in cartilage disorders

Current Gene Therapy

Volumn 9, Issue 4, 2009, Pages 306-315

  Schulze Tanzil, Gundula ^a   Zreiqat, Hala ^b   Sabat, Robert ^a   Kohl, Benjamin ^a   Halder, Andreas ^a   Müller, Riccarda D ^a   John, Thilo ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Articular cartilage; Chondrocytes; HO 1; IL 1 ; IL 10; OA; RA; TNF

Indexed keywords

CYCLOOXYGENASE 2; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 10; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHROPATHY; ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE COURSE; EXTRACELLULAR MATRIX; HUMAN; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; NONVIRAL GENE THERAPY; OSTEOARTHRITIS; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CARTILAGE DISEASES; CARTILAGE, ARTICULAR; CHONDROCYTES; DISEASE MODELS, ANIMAL; HEME OXYGENASE-1; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; JOINTS; MICE; OSTEOARTHRITIS; RABBITS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349966240     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309788921044     Document Type: Review

References (131)

1. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081-95.
2. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
3. Moroguchi A, Ishimura K, Okano K, Wakabayashi H, Maeba T, Maeta H. Interleukin-10 suppresses proliferation and remodeling of extracellular matrix of cultured human skin fibroblasts. Eur Surg Res 2004; 36: 39-44.
4. Reitamo S, Remitz A, Tamai K, Uitto J. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest 1994; 94: 2489-92.
5. Yamamoto T, Eckes B, Krieg T. Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1. Biochem Biophys Res Commun 2001; 281: 200-5.
6. Volk H, Asadullah K, Gallagher G, Sabat R, Grutz G. IL-10 and its homologs: important immune mediators and emerging immuno-therapeutic targets. Trends Immunol 2001; 22: 414-7.
7. Sabat R, Wallace E, Endesfelder S, Wolk K. IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets 2007; 11: 601-12.
8. Wolk K, Witte K, Witte E, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008; 83: 1181-93.
9. Wolk K, Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006; 17: 367-80.
10. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004; 21: 241-54.
11. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36: 1309-23.
12. Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009; 87: 523-36.
13. Baer R, Bankier AT, Biggin MD, et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984; 310: 207-11.
14. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 1990; 248: 1230-4.
15. Keravala A, Lechman ER, Nash J, Mi Z, Robbins PD. Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis. Arthritis Res Ther 2006; 8: R91.
16. Kuroda T, Maruyama H, Shimotori M, et al. Effects of viral interleukin 10 introduced by in vivo electroporation on arthrogen-induced arthritis in mice. J Rheumatol 2006; 33: 455-62.
17. Ding Y, Qin L, Kotenko SV, Pestka S, Bromberg JS. A single amino acid determines the immunostimulatory activity of interleukin 10. J Exp Med 2000; 191: 213-24.
18. Wolk K, Witte E, Reineke U, et al. Is there an interaction between interleukin-10 and interleukin-22? Genes Immun 2005; 6: 8-18.
19. Reineke U, Schneider-Mergener J, Glaser RW, et al. Evidence for conformationally different states of interleukin-10: binding of a neutralizing antibody enhances accessibility of a hidden epitope. J Mol Recognit 1999; 12: 242-8.
20. Finbloom DS, Winestock KD. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol 1995; 155: 1079-90.
21. Ito S, Ansari P, Sakatsume M, et al. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999; 93: 1456-63.
22. Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 2002; 8: 240-6.
23. Jung M, Sabat R, Kratzschmar J, et al. Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy. Eur J Immunol 2004; 34: 481-93.
24. Listopad J, Asadullah K, Sievers C, et al. Heme oxygenase-1 inhibits T cell-dependent skin inflammation and differentiation and function of antigen-presenting cells. Exp Dermatol 2007; 16: 661-70.
25. Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol 2004; 135: 64-73.
26. Wehinger J, Gouilleux F, Groner B, Finke J, Mertelsmann R, Weber-Nordt RM. IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett 1996; 394: 365-70.
27. Stephanou A, Latchman DS. Opposing actions of STAT-1 and STAT-3. Growth Factors 2005; 23: 177-82.
28. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-20.
29. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/ IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-8.
30. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815-22.
31. Creery WD, Diaz-Mitoma F, Filion L, Kumar A. Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Eur J Immunol 1996; 26: 1273-7.
32. Lingnau M, Hoflich C, Volk HD, Sabat R, Docke WD. Interleukin-10 enhances the CD14-dependent phagocytosis of bacteria and apoptotic cells by human monocytes. Hum Immunol 2007; 68: 730-8.
33. Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998; 28: 359-69.
34. Schoenbein C, Docke WD, Wolk K, et al. Long-term interleukin-10 presence induces the development of a novel, monocyte-derived cell type. Clin Exp Immunol 2008; 151: 306-16.
35. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353-60.
36. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996; 184: 19-29.
37. Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 1998; 160: 3188-93.
38. Wan YY, Flavell RA. The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol Rev 2006; 212: 114-30.
39. Boissier MC, Assier E, Biton J, Denys A, Falgarone G, Bessis N. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 2009; 76: 10-4.
40. Niiro H, Otsuka T, Izuhara K, et al. Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood 1997; 89: 1621-8.
41. Woods AM, Thompson SJ, Wooley PH, Panayi G, Klavinskis LS. Immune modulation of collagen-induced arthritis by intranasal cytokine gene delivery: a model for the therapy of rheumatoid arthritis. Arthritis Rheum 2005; 52: 3761-71.
42. Huizinga TW, Keijsers V, Yanni G, et al. Are differences in interleukin 10 production associated with joint damage? Rheumatology (Oxford) 2000; 39: 1180-8.
43. Woods JM, Sitabkhan Y, Koch AE. Gene therapy for rheumatoid arthritis: recent advances. Curr Gene Ther 2008; 8: 24-41.
44. Cuzzocrea S, Mazzon E, Dugo L, et al. Absence of endogeneous interleukin-10 enhances the evolution of murine type-II collagen-induced arthritis. Eur Cytokine Netw 2001; 12: 568-80.
45. Finnegan A, Kaplan CD, Cao Y, Eibel H, Glant TT, Zhang J. Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritis Res Ther 2003; 5: R18-24.
46. Johansson AC, Hansson AS, Nandakumar KS, Backlund J, Holmdahl R. IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J Immunol 2001; 167: 3505-12.
47. Joosten LA, Helsen MM, Saxne T, Heinegard D, van de Putte LB, van den Berg WB. Synergistic protection against cartilage destruction by low dose prednisolone and interleukin-10 in established murine collagen arthritis. Inflamm Res 1999; 48: 48-55.
48. Walmsley M, Katsikis PD, Abney E, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996; 39: 495-503.
49. Lubberts E, Joosten LA, Helsen MM, van den Berg WB. Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine 1998; 10: 361-9.
50. Lechman ER, Jaffurs D, Ghivizzani SC, et al. Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol 1999; 163: 2202-8.
51. Lubberts E, Joosten LA, Van Den Bersselaar L, et al. Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw. Clin Exp Immunol 2000; 120: 375-83.
52. Whalen JD, Lechman EL, Carlos CA, et al. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 1999; 162: 3625-32.
53. Jorgensen C, Apparailly F, Canovas F, et al. Systemic viral interleukin-10 gene delivery prevents cartilage invasion by human rheumatoid synovial tissue engrafted in SCID mice. Arthritis Rheum 1999; 42: 678-85.
54. Muller-Ladner U, Evans CH, Franklin BN, et al. Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model. Arthritis Rheum 1999; 42: 490-7.
55. Neumann E, Judex M, Kullmann F, et al. Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway. Gene Ther 2002; 9: 1508-19.
56. Choi JJ, Yoo SA, Park SJ, et al. Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. Clin Exp Immunol 2008; 153: 269-76.
57. Zheng ZH, Li XY, Ding J, Jia JF, Zhu P. Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 22-30.
58. Gelse K, von der Mark K, Schneider H. Cartilage regeneration by gene therapy. Curr Gene Ther 2003; 3: 305-17.
59. van Roon J, Wijngaarden S, Lafeber FP, Damen C, van de Winkel J, Bijlsma JW. Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression on monocytes and responsiveness to immune complex stimulation. J Rheumatol 2003; 30: 648-51.
60. van Roon JA, Lafeber FP, Bijlsma JW. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum 2001; 44: 3-12.
61. Lechman ER, Keravala A, Nash J, Kim SH, Mi Z, Robbins PD. The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen. Gene Ther 2003; 10: 2029-35.
62. van de Loo FA, van den Berg WB. Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. Rheum Dis Clin North Am 2002; 28: 127-49.
63. Siatskas C, Chan J, Field J, et al. Gene therapy strategies towards immune tolerance to treat the autoimmune diseases. Curr Gene Ther 2006; 6: 45-58.
64. Gould D, Yousaf N, Fatah R, Subang MC, Chernajovsky Y. Gene therapy with an improved doxycycline-regulated plasmid encoding a tumour necrosis factor-alpha inhibitor in experimental arthritis. Arthritis Res Ther 2007; 9: R7.
65. Quattrocchi E, Dallman MJ, Dhillon AP, Quaglia A, Bagnato G, Feldmann M. Murine IL-10 gene transfer inhibits established collagen-induced arthritis and reduces adenovirus-mediated inflammatory responses in mouse liver. J Immunol 2001; 166: 5970-8.
66. Adriaansen J, Khoury M, de Cortie CJ, et al. Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis 2007; 66: 1143-50.
67. Khoury M, Adriaansen J, Vervoordeldonk MJ, et al. Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. J Gene Med 2007; 9: 596-604.
68. Trachsel E, Bootz F, Silacci M, Kaspar M, Kosmehl H, Neri D. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 2007; 9: R9.
69. Leardini G, Salaffi F, Caporali R, Canesi B, Rovati L, Montanelli R. Direct and indirect costs of osteoarthritis of the knee. Clin Exp Rheumatol 2004; 22: 699-706.
70. Blanco GFJ. Catabolic events in osteoarthritic cartilage. Osteoarthritis Cartilage 1999; 7: 308-9.
71. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
72. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002; 39: 237-46.
73. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322: 547-9.
74. Towle CA, Hung HH, Bonassar LJ, Treadwell BV, Mangham DC. Detection of interleukin-1 in the cartilage of patients with osteoarthritis: a possible autocrine/paracrine role in pathogenesis. Osteoarthritis Cartilage 1997; 5: 293-300.
75. Green DM, Noble PC, Bocell JR, Jr., Ahuero JS, Poteet BA, Birdsall HH. Effect of early full weight-bearing after joint injury on inflammation and cartilage degradation. J Bone Joint Surg Am 2006; 88: 2201-9.
76. Malemud CJ, Islam N, Haqqi TM. Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs 2003; 174: 34-48.
77. Aigner T, Kim HA. Apoptosis and cellular vitality: issues in osteoarthritic cartilage degeneration. Arthritis Rheum 2002; 46: 1986-96.
78. Aizawa T, Kon T, Einhorn TA, Gerstenfeld LC. Induction of apoptosis in chondrocytes by tumor necrosis factor-alpha. J Orthop Res 2001; 19: 785-96.
79. Fischer BA, Mundle S, Cole AA. Tumor necrosis factor-alpha induced DNA cleavage in human articular chondrocytes may involve multiple endonucleolytic activities during apoptosis. Microsc Res Tech 2000; 50: 236-42.
80. Hulejova H, Baresova V, Klezl Z, Polanska M, Adam M, Senolt L. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine 2007; 38: 151-6.
81. Moretti B, Iannone F, Notarnicola A, et al. Extracorporeal shock waves down-regulate the expression of interleukin-10 and tumor necrosis factor-alpha in osteoarthritic chondrocytes. BMC Musculoskelet Disord 2008; 9: 16.
82. Maccoux LJ, Salway F, Day PJ, Clements DN. Expression profiling of select cytokines in canine osteoarthritis tissues. Vet Immunol Immunopathol 2007; 118: 59-67.
83. Deffaud J, Kirchmeyer M, Domagala F, et al. Modulatory effect of rhein on IL-1alpha-induced responses in human chondrocytes: a comparative study between antibody microarrays and specific ELISAs. Biorheology 2008; 45: 439-55.
84. Alaaeddine N, Di Battista JA, Pelletier JP, Kiansa K, Cloutier JM, Martel-Pelletier J. Inhibition of tumor necrosis factor alpha-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: distinct targeting in the signaling pathways. Arthritis Rheum 1999; 42: 710-8.
85. Riyazi N, Slagboom E, de Craen AJ, et al. Association of the risk of osteoarthritis with high innate production of interleukin-1beta and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation. Arthritis Rheum 2005; 52: 1443-50.
86. Botha-Scheepers S, Watt I, Slagboom E, et al. Innate production of tumour necrosis factor alpha and interleukin 10 is associated with radiological progression of knee osteoarthritis. Ann Rheum Dis 2008; 67: 1165-9.
87. Zhang X, Mao Z, Yu C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J Orthop Res 2004; 22: 742-50.
88. Jansen NW, Roosendaal G, Hooiveld MJ, et al. Interleukin-10 protects against blood-induced joint damage. Br J Haematol 2008; 142: 953-61.
89. Iannone F, De Bari C, Dell'Accio F, et al. Interleukin-10 and interleukin-10 receptor in human osteoarthritic and healthy chondrocytes. Clin Exp Rheumatol 2001; 19: 139-45.
90. Isomaki P, Punnonen J. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med 1997; 29: 499-507.
91. Jorgensen C, Apparailly F, Couret I, Canovas F, Jacquet C, Sany J. Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo. Immunology 1998; 93: 518-23.
92. Moo V, Sieper J, Herzog V, Muller BM. Regulation of expression of cytokines and growth factors in osteoarthritic cartilage explants. Clin Rheumatol 2001; 20: 353-8.
93. John T, Muller RD, Oberholzer A, et al. Interleukin-10 modulates pro-apoptotic effects of TNF-alpha in human articular chondrocytes in vitro. Cytokine 2007; 40: 226-34.
94. Müller RD, John T, Kohl B, et al. IL-10 overexpression differentially affects cartilage matrix gene expression in response to TNF-alpha in human articular chondrocytes in vitro. Cytokine 2008; 44: 377-85.
95. Radons J, Falk W, Schubert TE. Interleukin-10 does not affect IL-1-induced interleukin-6 and metalloproteinase production in human chondrosarcoma cells, SW1353. Int J Mol Med 2006; 17: 377-83.
96. Ritchlin C, Haas-Smith SA. Expression of interleukin 10 mRNA and protein by synovial fibroblastoid cells. J Rheumatol 2001; 28: 698-705.
97. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005; 2: 8.
98. Ferretti M, Gassner R, Wang Z, et al. Biomechanical signals suppress proinflammatory responses in cartilage: early events in experimental antigen-induced arthritis. J Immunol 2006; 177: 8757-66.
99. Ferretti M, Srinivasan A, Deschner J, et al. Anti-inflammatory effects of continuous passive motion on meniscal fibrocartilage. J Orthop Res 2005; 23: 1165-71.
100. Henrotin YE, Zheng SX, Labasse AH, Deby GP, Crielaard JM, Reginster JY. Modulation of human chondrocyte metabolism by recombinant human interferon. Osteoarthritis Cartilage 2000; 8: 474-82.
101. Morita Y, Yamamura M, Kawashima M, et al. Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium. Rheumatol Int 2001; 20: 49-54.
102. van Roon JA, van Roy JL, Gmelig-Meyling FH, Lafeber FP, Bijlsma JW. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996; 39: 829-35.
103. Dayer JM. [Cytokines and anti-cytokines in inflammatory rheumatism]. Rev Rhum Ed Fr 1994; 61: 173S-180S.
104. Nagano S, Otsuka T, Niiro H, et al. Molecular mechanisms of lipopolysaccharide-induced cyclooxygenase-2 expression in human neutrophils: involvement of the mitogen-activated protein kinase pathway and regulation by anti-inflammatory cytokines. Int Immunol 2002; 14: 733-40.
105. Wang Y, Lou S. Direct protective effect of interleukin-10 on articular chondrocytes in vitro. Chin Med J (Engl) 2001; 114: 723-5.
106. Abraham NG, Asija A, Drummond G, Peterson S. Heme oxygenase -1 gene therapy: recent advances and therapeutic applications. Curr Gene Ther 2007; 7: 89-108.
107. Fernandez P, Guillen MI, Gomar F, Alcaraz MJ. Expression of heme oxygenase-1 and regulation by cytokines in human osteoarthritic chondrocytes. Biochem Pharmacol 2003; 66: 2049-52.
108. Megias J, Guillen MI, Clerigues V, et al. Heme oxygenase-1 induction modulates microsomal prostaglandin E synthase-1 expression and prostaglandin E(2) production in osteoarthritic chondrocytes. Biochem Pharmacol 2009; 77: 1806-13.
109. Valvason C, Musacchio E, Pozzuoli A, Ramonda R, Aldegheri R, Punzi L. Influence of glucosamine sulphate on oxidative stress in human osteoarthritic chondrocytes: effects on HO-1, p22(Phox) and iNOS expression. Rheumatology (Oxford) 2008; 47: 31-5.
110. Guillen M, Megias J, Gomar F, Alcaraz M. Haem oxygenase-1 regulates catabolic and anabolic processes in osteoarthritic chondrocytes. J Pathol 2008; 214: 515-22.
111. Benallaoua M, Francois M, Batteux F, et al. Pharmacologic induction of heme oxygenase 1 reduces acute inflammatory arthritis in mice. Arthritis Rheum 2007; 56: 2585-94.
112. Zhou JH, Broussard SR, Strle K, et al. IL-10 inhibits apoptosis of promyeloid cells by activating insulin receptor substrate-2 and phosphatidylinositol 3′-kinase. J Immunol 2001; 167: 4436-42.
113. Oberholzer C, Oberholzer A, Bahjat FR, et al. Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. Proc Natl Acad Sci USA 2001; 98: 11503-8.
114. Feng L, Precht P, Balakir R, Horton WE, Jr. Evidence of a direct role for Bcl-2 in the regulation of articular chondrocyte apoptosis under the conditions of serum withdrawal and retinoic acid treatment. J Cell Biochem 1998; 71: 302-9.
115. Feng L, Balakir R, Precht P, Horton WE, Jr. Bcl-2 regulates chondrocyte morphology and aggrecan gene expression independent of caspase activation and full apoptosis. J Cell Biochem 1999; 74: 576-86.
116. Yagi R, McBurney D, Horton WE, Jr. Bcl-2 positively regulates Sox9-dependent chondrocyte gene expression by suppressing the MEK-ERK1/2 signaling pathway. J Biol Chem 2005; 280: 30517-25.
117. Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. J Clin Immunol 1999; 19: 350-64.
118. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997; 326 (Pt 1): 1-16.
119. Garg AK, Aggarwal BB. Reactive oxygen intermediates in TNF signaling. Mol Immunol 2002; 39: 509-17.
120. Heyninck K, Beyaert R. Crosstalk between NF-kappaB-activating and apoptosis-inducing proteins of the TNF-receptor complex. Mol Cell Biol Res Commun 2001; 4: 259-65.
121. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994; 179: 1517-27.
122. Qasimi P, Ming-Lum A, Ghanipour A, et al. Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production by macrophages. J Biol Chem 2006; 281: 6316-24.
123. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004; 22: 929-79.
124. Ghivizzani SC, Gouze E, Gouze JN, et al. Perspectives on the use of gene therapy for chronic joint diseases. Curr Gene Ther 2008; 8: 273-86.
125. Cucchiarini M, Madry H, Ma C, et al. Improved tissue repair in articular cartilage defects in vivo by rAAV-mediated overexpression of human fibroblast growth factor 2. Mol Ther 2005; 12: 229-38.
126. Madry H, Kaul G, Cucchiarini M, et al. Enhanced repair of articular cartilage defects in vivo by transplanted chondrocytes overexpressing insulin-like growth factor I (IGF-I). Gene Ther 2005; 12: 1171-9.
127. Madry H, Padera R, Seidel J, et al. Gene transfer of a human insulin-like growth factor I cDNA enhances tissue engineering of cartilage. Hum Gene Ther 2002; 13: 1621-30.
128. Madry H, Zurakowski D, Trippel SB. Overexpression of human insulin-like growth factor-I promotes new tissue formation in an ex vivo model of articular chondrocyte transplantation. Gene Ther 2001; 8: 1443-9.
129. Trippel S, Cucchiarini M, Madry H, Shi S, Wang C. Gene therapy for articular cartilage repair. Proc Inst Mech Eng [H] 2007; 221: 451-9.
130. Voigt M, Andree C, Kalt T, et al. Human recombinant EGF protein delivered by a biodegradable cell transplantation system. Tissue Eng 2002; 8: 263-72.
131. Knedla A, Riepl B, Lefevre S, et al. The therapeutic use of osmotic minipumps in the severe combined immunodeficiency (SCID) mouse model for rheumatoid arthritis. Ann Rheum Dis 2009; 68: 124-9.